E2F3

Across TCGA pan-cancer cohorts, E2F3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated E2F3 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher E2F3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated E2F3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where E2F3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.392	0.857	.003	21	view →
LSCC	OS	Median	All	0.912	0.705	.001	16	view →
LUAD	DFS	Quartile	III,IV	0.884	0.350	.001	9	view →
CCRCC	DFS	Quartile	III,IV	0.425	1.000	.036	2	view →
GBM	OS	Median	All	0.490	0.301	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

E2F3–HNSC (DFS)

Open the HNSC breakdown →